Skip to main content
Fig. 7 | Journal for ImmunoTherapy of Cancer

Fig. 7

From: Intratumoral immunotherapy with TLR7/8 agonist MEDI9197 modulates the tumor microenvironment leading to enhanced activity when combined with other immunotherapies

Fig. 7

MEDI9197 enhances efficacy when combined with I-O agents targeting OX40 or GITR. Tumor growth was measured in the single-flank B16-OVA tumor model following IT injection of MEDI9197 and IP dosing with GITRL FP or OX40 antibody. C57BL/6 J albino mice (n = 11–12/group) were implanted SC in the right flank with B16-OVA tumors on Day 0. On Days 8 and 15, mice were dosed IT with 0.4 μg MEDI9197 or Vehicle, and dosed IP with 25 mg/kg GITRL FP or 12 mg/kg OX40 Ab. a Tumor volume as a mean (with last observation carried forward) ± SEM up to Day 43 and (b) spider plots of individual tumor volume. Statistical analysis was performed using two-way ANOVA with Tukey’s multiple comparisons test. ***p = 0.0005, ****p = 0.0001

Back to article page